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journal homepage: www.elsevier.com/locate/ihjRestrictive cardiomyopathy is one of the most questioned
entity in cardiology; indeed the characteristics of restrictive
ﬁlling and reduced diastolic volume of either or both
ventricles, with normal or near-normal systolic function and
wall thickness, are shared by disorders with different causes
and prognosis.1 As illustrated in Table 1,2 restrictive cardio-
myopathy can be a part of systemic involvement (such as
amyloidosis, sarcoidosis or scleroderma) or expression of a
disorder involving only the heart (such as endomyocardial
ﬁbrosis).
First of all, when suspecting a restrictive pattern, it is proper
to rule out the main differential diagnosis, namely, chronic
constrictive pericarditis, especially in the Indian milieu, where
tuberculosis has a prevalence of 5 cases/1000 people.3 This is
fundamental due to its therapy, which is primarily surgery,
while the standard of care for all restrictive cardiomyopathies is
medical therapy (although surgical treatment can be offered for
speciﬁc diseases such as endomyocardial ﬁbrosis). Therefore,
diagnosis of restrictive cardiomyopathy and its differentiation
from constrictive pericarditis are crucial for planning manage-
ment, even more so that if the cause of restrictive cardiomyop-
athy is known, it can impact on the medical therapy.
In the struggle for a better deﬁnition and quantiﬁcation of
myocardial involvement in such a different disease with
similar manifestation, clinical setting and imaging technique
are overhelming, with echocardiography as a ﬁrst step at the
patient's bed. Despite newer advances such as tissue Doppler,
strain and speckle imaging and 3D echocardiography can often
demonstrate abnormal function indicating myocardial dis-
ease, but in many patients only cardiac magnetic resonance
could provide the ﬁnal answer.4
However, just over the diagnosis, cardiac function assess-
ment is the main goal for imaging techniques, because it may
not only guide the therapeutic approach but also give
prognostic information.
In this issue of the Journal Sumar Karna et al.5 applied the
conventional echocardiographic technique and the tissue
Doppler imaging in order to identify markers of myocardial
function in a particular form of restrictive cardiomyopathy,
that is, systemic sclerosis and correlated echocardiographic
ﬁndings to clinical features of the disease.§ This editorial is pertaining to the article: Right ventricular thick
sclerosis: A Doppler tissue imaging study.Scleroderma is a multisystem disorder characterized by
extensive vascular damage and ﬁbrosis of the skin and internal
organs. Cardiac involvement consists of degeneration of
myocardial ﬁbers and irregular areas of interstitial ﬁbrosis,
starting from subendocardium. In India, systemic sclerosis
follows the same epidemiology and pattern of clinical
manifestations as in the western countries, albeit with varying
frequency from the northern compared to the southern part of
the country.6
Because the prognosis for patients with systemic sclerosis
also correlates with the presence of pulmonary hypertension
and ipso facto with the right ventricular function, they
especially focused on that.
Truthfully, imaging of the right ventricle has gained a
worldwide popularity in the last few years; the thin wall, the
overall asymmetric shape, and the anatomically distinct
inﬂow and outﬂow tracts that are placed in different planes
make the right ventricle challenging to assess by any imaging
modality. Here the researcher demonstrated right ventricle
thickness as a single most important predictor of Tei index of
both ventricles, because Tei index has been proven to be a
marker of global and regional myocardial performance by
invasive study.7 Therefore they concluded that right ventricle
wall thickness may be a simple predictor of global myocardial
performance in SSc patients.
Being easy and fast to measure, it would be intriguing to
infer that it may be an important parameter to check when
evaluating right ventricular function in restrictive cardiomy-
opathies in general, as JASE guidelines yet suggest to suspect
pulmonary overload.8 In India, restrictive cardiomyopathy is a
frequent diagnosis, and the vast majority of patients present-
ing with this illness are affected by endomyocardial ﬁbrosis (an
obliterative cardiomyopathy characterized by ﬁbrotic thicken-
ing and obliteration of the endocardium of both ventricle in
ﬁfty per cent of cases and the only right ventricle in the half of
the remaining ones; etiology is today not deﬁnitively proven),
especially in the southern zones.9
Hyper-eosinophilic syndrome, also known as Loefﬂer
endocarditis is a different entity with a similar pathological
outcome; it is seen in non-tropical counties and could be
secondary to neoplasm, infection, allergic or be idiopathic. It isness as predictor of global myocardial performance in systemic
Table 1 – Causes of restrictive cardiomyopathy (adapted
from 2).
Myocardial
Non-inﬁltrative
Scleroderma
Idiopathic cardiomyopathy
Familial cardiomyopathy
Hypertrophic cardiomyopathy
Diabetic cardiomyopathy
Pseudoxanthoma elasticum
Inﬁltrative
Amyloidosis
Sarcoidosis
Fabry's disease
Gaucher's disease
Haemochromatosis
Hurler's disease
Fatty inﬁltration
Storage diseases
Glycogen storage disease
Endomyocardial
Endomyocardial ﬁbrosis
Hyper-eosinophilic syndrome
Carcinoid heart disease
Metastatic cancers
Radiation
Toxic effects of anthracycline
Drugs causing ﬁbrous endocarditis (serotonin, methysergide,
ergotamine, mercurial agents, and busulfan)
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the increase in socioeconomic status, endomyocardial disease
would decline, with their place taken by diabetes, scleroderma,
and amyloidosis.10
Correct evaluation of both ventricles in such a different
form of cardiac illness presenting with restrictive ﬁlling is
therefore important, and the forgotten ventricle deserves these
attentions due to the implications on treatment and prognosis
of its involvement.
Studies like this one from Sumar Karna et al.5 do not
exemplify the outer reach of research in this ﬁeld, which are
actually represented by strain and 3D echocardiography and
magnetic resonance imaging, but the hope is that they may
stimulate a continuous application on the bedside of the
researcher eye together with the clinicians' one, for a better
understanding of the role of right ventricle in restrictive
cardiomyopathies.r e f e r e n c e s
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